Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abcam plc stock logo
ABCM
Abcam
$23.99
$23.88
$12.48
$25.32
$5.50B0.863.08 million shs3,300 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$7.08
-14.3%
$8.15
$0.85
$93.60
$46.28M2.42914,650 shs376,612 shs
LianBio stock logo
LIAN
LianBio
$0.05
$0.30
$0.27
$4.99
$5.67M0.231.04 million shs1 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abcam plc stock logo
ABCM
Abcam
0.00%0.00%0.00%0.00%0.00%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-14.29%-8.05%-55.25%+505.13%-92.92%
LianBio stock logo
LIAN
LianBio
0.00%+8.92%-87.26%-73.75%-82.76%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abcam plc stock logo
ABCM
Abcam
N/AN/AN/AN/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.3788 of 5 stars
1.00.00.00.02.20.80.6
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abcam plc stock logo
ABCM
Abcam
0.00
N/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$2.00-71.75% Downside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abcam plc stock logo
ABCM
Abcam
$379.70M14.49$0.60 per share40.17$3.92 per share6.12
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$60K660.80N/AN/A($695.52) per share-0.01
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abcam plc stock logo
ABCM
Abcam
-$10.51MN/A0.0042.092.19N/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A

Latest ABCM, LIAN, HYPD, and PHXM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abcam plc stock logo
ABCM
Abcam
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abcam plc stock logo
ABCM
Abcam
N/A
1.35
1.00
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A
0.34
0.34
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A

Institutional Ownership

CompanyInstitutional Ownership
Abcam plc stock logo
ABCM
Abcam
90.45%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
LianBio stock logo
LIAN
LianBio
74.85%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%

Insider Ownership

CompanyInsider Ownership
Abcam plc stock logo
ABCM
Abcam
6.73%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
10.86%
LianBio stock logo
LIAN
LianBio
7.59%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abcam plc stock logo
ABCM
Abcam
1,760229.27 million213.84 millionOptionable
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
405.60 million5.00 millionOptionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data

Recent News About These Companies

Phaxiam Therapeutics S.A.
PHAXIAM Reports Third-Quarter 2024 Financial Information

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abcam stock logo

Abcam NASDAQ:ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$7.08 -1.18 (-14.29%)
As of 08/1/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)
As of 07/30/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 07/31/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.